Login / Signup

Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.

Haggai Bar-YosephN LevharL SelingerU ManorM YavzoriO PicardE FudimUri KopylovR EliakimS Ben-HorinY ChowersBella Ungar
Published in: Alimentary pharmacology & therapeutics (2017)
Infliximab levels below 6.8 μg/mL and antibodies to infliximab levels above 4.3 μg/mL-eq before the second infusion are associated with primary nonresponse, especially among Crohn's disease patients.
Keyphrases
  • ulcerative colitis
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • low dose
  • peritoneal dialysis
  • prognostic factors
  • bone marrow
  • drug induced